Autopsy report · NCT03013127

A Study of Pembrolizumab in Patients With Relapsed Or Metastatic Osteosarcoma Not Eligible for Curative Surgery

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Inclusion of patients was stopped because ≤2 patients had clinical benefit.”

The sponsor’s own words in the registry.

Life of this trial

Registered 5 months before it started.
Ran for about 1 year 8 months before it stopped.
12 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: Oslo University Hospital
Sponsor type: University, hospital or other
Conditions: Osteosarcoma
Interventions: Pembrolizumab
Participants: 12
Sites: 2
Countries: Italy, Norway

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.